SAFETY DATA SHEET

Products Containing Dako Antibody Diluent

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier

Product name : Products Containing Dako Antibody Diluent

Part no. : GA051, GA052, GA053, GA054, GA055, GA058, GA059, GA060, GA061, GA062, GA067, GA074, GA075, GA077, GA080, GA084, GA090, GA600, GA750, IK001, IK002, IK004, IR002, IR051, IR052, IR053, IR054, IR055, IR056, IR057, IR058, IR059, IR060, IR061, IR062, IR066, IR067, IR068, IR069, IR072, IR074, IR075, IR076, IR077, IR079, IR080, IR082, IR084, IR085, IR086, IR087, IR088, IR089, IR092, IR093, IR094, IR600, IR750, IS750, IX018, IX019, M0617, M0630, M0634, M0635, M3501, M3502, M3503, M3504, M3505, M3512, M3515, M3517, M3525, M3528, M3539, M3556, M3562, M3568, M3569, M3571, M3575, M3612, M3615, M3616, M3619, M3620, M3621, M3623, M3625, M3626, M3627, M3631, M3632, M3636, M3638, M3639, M3640, M3641, M3642, M3643, M3646, M3647, M3649, M3651, M3653, M3666, M7019, M7235, M7237, M7240, M7271, M7310

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Laboratory use
Container type: Bottle
GA051 // FLEX Monoclonal Mouse anti-Human Cytokeratin, HMW, Clone 34βE12 RTU (Omnis) // 12 mL
GA052 // FLEX Monoclonal Mouse anti-Human Melanosome, Clone HMB45 RTU (Omnis) // 12 mL
GA053 // FLEX Monoclonal Mouse anti-Human Cytokeratin, Clone AE1/AE3 (Omnis) // 12 mL
GA054 // FLEX Monoclonal Mouse anti-Human Caldesmon, Clone h-CD (Omnis) // 12 mL
GA055 // /FLEX Monoclonal Mouse Anti-Human Wilms' Tumor 1 (WT1) // 12 ml Protein, Clone 6F-H2, RTU (Dako Omnis) // 12 mL
GA058 // /FLEX Monoclonal Mouse Anti-Human Inhibin ¿, Clone R1, RTU (Dako Omnis) // 12 mL
GA059 // FLEX Monoclonal Mouse anti-Human E-Cadherin, Clone NCH-38 (Omnis) // 12 mL
GA060 // FLEX Monoclonal Rabbit anti-Human AMACR, Clone 13H4-38 (Omnis) // 12 mL
GA061 // FLEX Monoclonal Mouse anti-Human CD15, Clone Carb-3 (Omnis) // 12 mL
GA062 // /FLEX Monoclonal Mouse Anti-Human CD15, Clone Carb-3, RTU (Dako Omnis) // 12 mL
GA067 // /FLEX Monoclonal Mouse Anti-Myogenin, Clone F5D, RTU (Dako Omnis) // 12 mL
GA074 // /FLEX Monoclonal Mouse Anti-Human Mammaglobin, Clone 304-1A5, RTU (Dako Omnis) // 12 mL
GA075 // /FLEX Monoclonal Mouse Anti-Human Renal Cell Carcinoma Marker, Clone SPM314, RTU (Dako Omnis) // 12 mL
GA077 // /FLEX Monoclonal Mouse Anti-Human Gross Cystic Disease Fluid Protein-15, Clone 23A3, RTU (Dako Omnis) // 12 mL
GA080 // /FLEX Monoclonal Mouse Anti-Human CDX2, Clone DAK-CDX2, RTU (Dako Omnis) // 12 mL
GA083 // FLEX Monoclonal Rabbit Anti-Human Cyclin D1, Clone EP12, Ready-to-Use (Dako Omnis) // 12 mL
GA084 // /FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor ¿, Clone EP1, RTU (Dako Omnis) // 12 mL
GA090 // FLEX Monoclonal Mouse Anti-Human Progesterone Receptor Clone PgR 1294 RTU (Dako Omnis) // 12 mL
GA600 // /FLEX Universal Negative Control, Rabbit, RTU (Dako Omnis) // 12 mL
GA750 // FLEX Universal Negative Control Mouse RTU // 12 mL
IK001 // DuoFLEX Cocktail anti-S100 anti-Tyrosinase anti-Melan-A RTU // 6 mL
IK002 // DuoFLEX Cocktail anti-CD3 anti-CD20cy RTU // 6 mL
IK004 // DuoFLEX Cocktail anti-AMACR anti-Cytokeratin HMW anti-Cytokeratin 5/6

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

RTU // 6 mL
IR002 // /FLEX Polyclonal Guinea Pig Anti-Insulin, RTU (Link) // 12 mL
IR051 // /FLEX Monoclonal Mouse Anti-Human Cytokeratin, High Molecular Weight, Clone 34ßE12, RTU (Link) // 12 mL
IR052 // FLEX Monoclonal Mouse anti-Human Melanosome, Clone HMB45 RTU (Link) // 12 mL
IR053 // FLEX Monoclonal Mouse anti-Human Cytokeratin, Clone AE1/AE3 RTU (Link) // 12 mL
IR054 // FLEX Monoclonal Mouse anti-Human Caldesmon, Clone h-CD RTU (Link) // 12 mL
IR055 // FLEX Monoclonal Mouse anti-Human Wilms' Tumor 1 (WT1) Protein, Clone 6F-H2 RTU (Link) // 12 mL
IR056 // FLEX Monoclonal Mouse anti-Thyroid Transcription Factor, TTF-1, Clone 8G7G3/1 RTU (Link) // 12 mL
IR057 // FLEX Monoclonal Mouse anti-Human CD99, MIC2 Ewing's Sarcoma Marker, Clone 12E7 RTU (Link) // 12 mL
IR058 // FLEX Monoclonal Mouse anti-Human Inhibin a, Clone R1 RTU (Link) // 12 mL
IR059 // FLEX Monoclonal Mouse anti-Human E-Cadherin, Clone NCH-38 RTU (Link) // 12 mL
IR060 // FLEX Monoclonal Rabbit anti-Human AMACR, Clone 13H4 RTU (Link) // 12 mL
IR061 // FLEX Monoclonal Mouse anti-Human Tyrosinase, Clone T311 RTU (Link) // 12 mL
IR062 // FLEX Monoclonal Mouse anti-Human CD15, Clone Carb-3 RTU (Link) // 12 mL
IR066 // FLEX Monoclonal Mouse anti-Human Smooth Muscle Myosin Heavy Chain, Clone SMMS-1 RTU (Link) // 12 mL
IR067 // FLEX Monoclonal Mouse anti-Myogenin, Clone F5D RTU (Link) // 12 mL
IR068 // FLEX Monoclonal Mouse anti-Human Progesterone Receptor, Clone PgR 636 RTU (Link) // 12 mL
IR069 // FLEX Monoclonal Mouse anti-Human CD1a, Clone 010 RTU (Link) // 12 mL
IR072 // FLEX Monoclonal Mouse anti-Human Podoplanin, Clone D2-40 RTU (Link) // 12 mL
IR074 // FLEX Monoclonal Mouse anti-Human Mammaglobin, Clone 304-1A5 RTU (Link) // 12 mL
IR075 // FLEX Monoclonal Mouse anti-Human Renal Cell Carcinoma Marker, Clone SPM314 RTU (Link) // 12 mL
IR076 // FLEX Monoclonal Mouse anti-Villin, Clone 1D2 C3 RTU (Link) // 12 mL
IR077 // FLEX Monoclonal Mouse anti-Human Gross Cystic Disease Fluid Protein-15, Clone 23A3 RTU (Link) // 12 mL
IR079 // FLEX Monoclonal Mouse anti-Human MutL Protein Homolog 1, Clone ES05 RTU (Link) // 12 mL
IR080 // FLEX Monoclonal Mouse anti-Human CDX2, Clone DAK-CDX2 RTU (Link) // 12 mL
IR082 // FLEX Monoclonal Mouse anti-Human CD5, Clone 4C7 RTU (Link) // 12 mL
IR084 // FLEX Monoclonal Rabbit anti-Human Estrogen Receptor α, Clone EP1 RTU (Link) // 12 mL
IR085 // FLEX Monoclonal Mouse anti-Human MutS Protein Homolog 2, Clone FE11 RTU (Link) // 12 mL
IR086 // FLEX Monoclonal Rabbit anti-Human MutS Protein Homolog 6, Clone EP49 RTU (Link) // 12 mL
IR087 // FLEX Monoclonal Rabbit anti-Human Postmeitic Segregation Increased 2, Clone EP51 RTU (Link) // 12 mL
IR088 // FLEX Monoclonal Mouse anti-Human Prostein, Clone 10E3 RTU (Link) // 12 mL
IR089 // FLEX Monoclonal Mouse anti-Human Prostate Specific Membrane Antigen, Clone 3E6 RTU (Link) // 12 mL
IR092 // FLEX Monoclonal Mouse Octamer-Binding Transcription Factor 3/4, Clone N1NK RTU (Link) // 12 mL
IR093 // FLEX Monoclonal Rabbit anti-Human Terminal Deoxynucleotidyl Transferase, Clone EP266 RTU (Link) // 12 mL
IR094 // FLEX Monoclonal Rabbit anti-Human Cytokeratin 8/18, Clone EP17/EP30 RTU (Link) // 12 mL
IR600 // FLEX Negative Control Rabbit Immunoglobulin Fraction of Serum from Non-immunized Rabbits RTU // 12 mL

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

IR750 // FLEX Negative Control Mouse Cocktail of Mouse, RTU (Link) / 12 mL
IS750 // FLEX Negative Control Mouse Cocktail of Mouse, RTU // 6 mL
IX018 // Monoclonal Mouse Anti-Human Proinsulin, Clone 3B1 // 50 ml - 3 L
IX019 // Monoclonal Mo a Hu Proinsulin, Clone A6C9 // 50 ml - 3 L
M0617 // Monoclonal Mouse Anti-Thrombomodulin, Clone 1009 // 1 mL
M0630 // Monoclonal Mouse Anti-Human Cytokeratin, High Molecular Weight, Clone 34βE12 // 1 mL
M0634 // Monoclonal Mouse Anti-Human Melanosome, Clone HMB-45 // 0,2 ml, 1 ml
M0635 // Monoclonal Mouse Anti-Human Muscle Actin, Clone HHF35 // 1 mL
M3501 // Monoclonal Mouse Anti-Adrenocorticotropin (ACTH), Clone 02A3 // 1 mL
M3502 // Monoclonal Mouse Anti-Human Luteinizing Hormone (LH), Clone C93 // 1 mL
M3503 // Monoclonal Mouse Anti-Human Thyroid-Stimulating Hormone (TSH), Clone 0042 // 1 mL
M3504 // Monoclonal Mouse Anti-Human Follicle-Stimulating Hormone (FSH), Clone C10 // 1 mL
M3505 // Monoclonal Mouse Anti-Human Mesothelial Cell, Clone HBME-1 // 1 mL
M3512 // Monoclonal Mouse Anti-Human MyoD1, Clone 5.8A // 1 mL
M3515 // Monoclonal Mouse Anti-Human Cytokeratin, Clone AE1 // AE3 // 0,2 mL, 1 mL
M3517 // Monoclonal Mouse Anti-CA 19-9, Clone 116-NS-19-9 // 1 mL
M3525 // Monoclonal Mouse Anti-Human Epithelial-Related Antigen, Clone MOC-31 // 1 mL
M3528 // Monoclonal Mouse Anti-Human Papillomavirus (HPV), Clone K1H8 // 1 mL
M3539 // Monoclonal Mouse Anti-Human Beta-Catenin, Clone β-Catenin-1 // 1 mL
M3556 // Monoclonal Mouse Anti-Human Calponin, Clone CALP // 1 mL
M3562 // Monoclonal Mouse Anti-Human Androgen Receptor, Clone AR441 // 1 mL
M3568 // Monoclonal Mouse Anti-Human Progesterone Receptor, Clone PgR 1294 // 1 mL
M3569 // Monoclonal Mouse Anti-Human Progesterone Receptor, Clone PgR 636 // 0,2 mL, 1 mL
M3571 // Monoclonal Mouse Anti-Human CD1a, Clone O10 010 // 1 mL
M3575 // Monoclonal Mouse Anti-Thyroid Transcription Factor, Clone 8G7G3 // 1 // 0,2 mL, 1 mL
M3612 // Monoclonal Mouse Anti-Human E-Cadherin, Clone NCH-38 // 0,2 mL, 1 ml
M3615 // Monoclonal Mouse Anti-Human P501S Prostein, Clone 10E3 // 0,2 mL, 1 mL
M3616 // Monoclonal Rabbit Anti-Human P504S AMACR, Clone 13H4 // 0,2 mL, 1 mL
M3619 // Monoclonal Mouse Anti-Human D2-40, Clone D2-40 // 0,2 mL, 1 mL
M3620 // Monoclonal Mouse Anti-Human Prostate-Specific Membrane Antigen, Clone 3E6 // 0,2 mL, 1 mL
M3621 // Monoclonal Mouse Anti-Human MITF, Clone D5 // 0,2 mL
M3623 // Monoclonal Mouse Anti-Human Tyrosinase, Clone T311 // 0,2 mL
M3625 // Monoclonal Mouse Anti-Human Mammaglobin, Clone 304-1A5 // 0,2 mL
M3626 // Monoclonal Mouse Anti-Human L523S Protein IMP3, Clone 69.1 // 0,2 mL
M3627 // Monoclonal Mouse Anti-Human PTEN, Clone 6H2.1 // 0,2 mL
M3631 // Monoclonal Mouse Anti-Human CD15, Clone Carb-3 // 0,2 mL, 1 mL
M3632 // Monoclonal Mouse Anti-Human Renal Cell Carcinoma Marker, Clone SPM314 // 1 mL
M3636 // Monoclonal Mouse Anti-Human CDX2, Clone DAK-CDX2 // 0,2 mL, 1 mL
M3638 // Monoclonal Mouse Anti-Human Gross Cystic Disease Fluid Protein-15, Clone 23A3 // 1 mL
M3639 // Monoclonal Mouse Anti-Human MSH2, Clone FE11 // 0,2 mL, 1 mL
M3640 // Monoclonal Mouse Anti-Human MutL Protein Homolog 1, Clone ES05 // 0,2 mL, 1 mL
M3641 // Monoclonal Mouse Anti-Human CD5, Clone 4C7 // 1 mL
M3642 // Monoclonal Rabbit Anti-Human Cyclin D1, Clone EP12 // 1 mL
M3643 // Monoclonal Rabbit Anti-Human Estrogen Receptor ¿, Clone EP1 // 0,2 mL, 1 mL
M3646 // Monoclonal Rabbit Anti-Human MutS Protein Homolog 6, Clone EP49 // 0,2 mL, 1 mL
M3647 // Monoclonal Rabbit Anti-Human Postmeiotic Segregration Increased 2, Clone EP51 // 0,2 mL, 1 mL
M3649 // Monoclonal Mouse Anti-Human Octamer-Binding Transcription Factor 3 // 4, Clone N1NK // 0,2 mL, 1 mL

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

M3651 // Monoclonal Rabbit Anti-Human Terminal Deoxynucleotidyl Transferase (TdT), Clone EP266 // 1 mL
M3653// Monoclonal Mouse Anti-Human PD-L1 Clone 22C3 // 0,2 mL
M3666// Monoclonal Mouse Anti-Human PD-L1, Clone 22C3/ 0,2mL
M7019 // Monoclonal Mouse Anti-Human Cytokeratin 20, Clone Ks20.8 // 0,2 mL, 1 mL
M7235 // Monoclonal Mouse Anti-Human Grannzyme B, Clone GrB-7 // 1 mL
M7237 // Monoclonal Mouse Anti-Human Cytokeratin 5 // 6, Clone D5 // 16 B4 // 0,2 mL, 1 mL
M7240 // Monoclonal Mouse Anti-Human Ki-67 Antigen, Clone MIB-1 // 0,2 mL, 1 mL
M7271 // Monoclonal Mouse Anti-Human CD57, Clone TB01 // 0,2 mL
M7310 // Monoclonal Mouse Anti-Human CD4, Clone 4B12 // 0,2 mL, 1 mL
Reference number: SDS347

Uses advised against : None known.

1.3 Details of the supplier of the safety data sheet

Agilent Technologies, Inc.
5301 Stevens Creek Blvd
Santa Clara, CA 95051, USA
Tel: +1 800 227 9770

Agilent Technologies Singapore (International) Pte Ltd.
No. 1 Yishun Avenue 7
Singapore, 768923
Tel. (65) 6276 2622

Agilent Technologies Denmark ApS
Produktionsvej 42
2600 Glostrup,
Denmark
Tel. +45 44 85 95 00

www.Agilent.com

e-mail address of person responsible for this SDS : sds@agilent.com

1.4 Emergency telephone number

Emergency telephone number (with hours of operation) : CHEMTREC®: +353 1 901 4670

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended.

Ingredients of unknown toxicity : Percentage of the mixture consisting of ingredient(s) of unknown acute dermal toxicity: 1 - 10%
Percentage of the mixture consisting of ingredient(s) of unknown acute inhalation toxicity: 1 - 10%
Percentage of the mixture consisting of ingredient(s) of unknown acute oral toxicity: 1 - 10%

Ingredients of unknown ecotoxicity : Contains 1% of components with unknown hazards to the aquatic environment

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

SECTION 2: Hazards identification

2.2 Label elements

Signal word : No signal word.

Hazard statements : No known significant effects or critical hazards.

Precautionary statements

Prevention : Not applicable.

Response : Not applicable.

Storage : Not applicable.

Disposal : Not applicable.

Supplemental label elements : Not applicable.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles : Not applicable.

Special packaging requirements

Tactile warning of danger : Not applicable.

2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII : This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

Other hazards which do not result in classification : None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures : Mixture

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.

Inhalation : Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Skin contact : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.

Ingestion : Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

Protection of first-aiders : No action shall be taken involving any personal risk or without suitable training.

4.2 Most important symptoms and effects, both acute and delayed

SECTION 4: First aid measures

Potential acute health effects

Eye contact : No known significant effects or critical hazards.

Inhalation : No known significant effects or critical hazards.

Skin contact : No known significant effects or critical hazards.

Ingestion : No known significant effects or critical hazards.

Over-exposure signs/symptoms

Eye contact : No specific data.

Inhalation : No specific data.

Skin contact : No specific data.

Ingestion : No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Specific treatments : No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Use an extinguishing agent suitable for the surrounding fire.

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture : In a fire or if heated, a pressure increase will occur and the container may burst.

Hazardous combustion products : Decomposition products may include the following materials:
carbon dioxide
carbon monoxide
nitrogen oxides
sulfur oxides
phosphorus oxides

5.3 Advice for firefighters

Special precautions for fire-fighters : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.

For emergency responders : If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

SECTION 6: Accidental release measures

6.2 Environmental precautions : Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

6.4 Reference to other sections : See Section 1 for emergency contact information.
See Section 8 for information on appropriate personal protective equipment.
See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Protective measures : Put on appropriate personal protective equipment (see Section 8).

Advice on general occupational hygiene : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Storage : Specific storage conditions: Please consult the label.
Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

Recommendations : Industrial applications, Professional applications.

Industrial sector specific solutions : Not available.

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

No exposure limit value known.

Biological exposure indices

No exposure indices known.

Recommended monitoring procedures : Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

Not available.

SECTION 8: Exposure controls/personal protection

PNECs

Not available.

8.2 Exposure controls

Appropriate engineering controls : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Individual protection measures

Hygiene measures : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hand protection : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Body protection : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Environmental exposure controls : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

Appearance

Physical state : Liquid. [Clear.]

Colour : Colourless.

Odour : Odourless.

Odour threshold : Not available.

Melting point/freezing point : 0°C

Boiling point or initial boiling point and boiling range : 100°C

Flammability : Not applicable.

Lower and upper explosion limit/ flammability limit : Not available.

SECTION 9: Physical and chemical properties

Flash point : Not available.

Auto-ignition temperature : Not available.

Decomposition temperature : Not available.

pH : 7.6

Viscosity : Dynamic (room temperature): Not available.
Kinematic (room temperature): Not available.
Kinematic (40°C): Not available.

Solubility :

Media	Result
water	Soluble

Partition coefficient: n-octanol/water : Not applicable.

Vapour pressure :

Ingredient name	Vapour Pressure at 20˚C			Vapour pressure at 50˚C		
	mm Hg	kPa	Method	mm Hg	kPa	Method
water	17.5	2.3	-	92.258	12.3	-

Relative density : Not available.

Relative vapour density : Not available.

Particle characteristics

Median particle size : Not applicable.

9.2 Other information

9.2.1 Information with regard to physical hazard classes

Explosive properties : Not available.

Oxidising properties : Not available.

9.2.2 Other safety characteristics

Miscible with water : Yes.

Evaporation rate : Not available.

Physical/chemical properties comments : Not available.

SECTION 10: Stability and reactivity

10.1 Reactivity : No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability : The product is stable.

10.3 Possibility of hazardous reactions : Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid : No specific data.

10.5 Incompatible materials : May react or be incompatible with oxidising materials.

10.6 Hazardous decomposition products : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Conclusion/Summary [Product] : Not available.

Acute toxicity estimates

N/A

Skin corrosion/irritation

Conclusion/Summary [Product] : Not available.

Serious eye damage/eye irritation

Conclusion/Summary [Product] : Not available.

Respiratory corrosion/irritation

Conclusion/Summary [Product] : Not available.

Respiratory or skin sensitization

Skin

Conclusion/Summary [Product] : Not available.

Respiratory

Conclusion/Summary [Product] : Not available.

Germ cell mutagenicity

Conclusion/Summary [Product] : Not available.

Carcinogenicity

Conclusion/Summary [Product] : Not available.

Reproductive toxicity

Conclusion/Summary [Product] : Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on likely routes of exposure : Not available.

Potential acute health effects

SECTION 11: Toxicological information

Eye contact : No known significant effects or critical hazards.

Inhalation : No known significant effects or critical hazards.

Skin contact : No known significant effects or critical hazards.

Ingestion : No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact : No specific data.

Inhalation : No specific data.

Skin contact : No specific data.

Ingestion : No specific data.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Short term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Long term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Potential chronic health effects

Conclusion/Summary [Product] : Not available.

General : No known significant effects or critical hazards.

Carcinogenicity : No known significant effects or critical hazards.

Mutagenicity : No known significant effects or critical hazards.

Reproductive toxicity : No known significant effects or critical hazards.

11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

SECTION 12: Ecological information

12.1 Toxicity

Conclusion/Summary [Product] : Not available.

12.2 Persistence and degradability

Not available.

Conclusion/Summary [Product] : Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Soil/water partition coefficient

Not available.

Results of PMT and vPvM assessment

SECTION 12: Ecological information

This mixture does not contain any substances that are assessed to be a PMT or a vPvM.

Mobility : Not available.

Conclusion/Summary : The product does not meet the criteria to be considered as a PMT or vPvM.

12.5 Results of PBT and vPvB assessment

Regulation (EC) No. 1907/2006 [REACH]

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

Regulation (EC) No. 1272/2008 [CLP]

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

Conclusion/Summary Regulation (EC) No. 1272/2008 [CLP] : The product does not meet the criteria to be considered as a PBT or vPvB.

12.6 Endocrine disrupting properties

Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

12.7 Other adverse effects

No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste : Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.

Packaging

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Special precautions : This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	IMDG	IATA
14.1 UN number or ID number	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-
14.3 Transport hazard class(es)	-	-	-
14.4 Packing group	-	-	-

SECTION 14: Transport information

14.5 Environmental hazards	No.	No.	No.

Additional information

14.6 Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments : Not available.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

None of the components are listed / The components are not impacted by a restriction

Labelling : Not applicable.

Other EU regulations

Ozone depleting substances (EU 2024/590)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Persistent Organic Pollutants

Not listed.

Seveso Directive

This product is not controlled under the Seveso Directive.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

Australia : Not determined.

Canada : Not determined.

SECTION 15: Regulatory information

China : All components are listed or exempted.

Eurasian Economic Union : **Russian Federation inventory**: Not determined.

Japan : **Japan inventory (CSCL)**: Not determined.
Japan inventory (ISHL): Not determined.

New Zealand : Not determined.

Philippines : Not determined.

Republic of Korea : Not determined.

Taiwan : Not determined.

Thailand : Not determined.

Turkey : Not determined.

United States : All components are active or exempted.

Viet Nam : Not determined.

15.2 Chemical safety assessment : This product contains substances for which Chemical Safety Assessments might still be required.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms : ADN = European Provisions concerning the International Carriage of Dangerous Goods by Inland Waterway
ADR = The European Agreement concerning the International Carriage of Dangerous Goods by Road
ATE = Acute Toxicity Estimate
B = Bioaccumulative
BCF = Bioconcentration Factor
CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]
DMEL = Derived Minimal Effect Level
DNEL = Derived No Effect Level
EUH statement = CLP-specific Hazard statement
IATA = International Air Transport Association
IMDG = International Maritime Dangerous Goods
IMO = International Maritime Organization
M = Mobile
N/A = Not available
P = Persistent
PBT = Persistent, Bioaccumulative and Toxic
PMT = Persistent, Mobile and Toxic
PNEC = Predicted No Effect Concentration
RID = The Regulations concerning the International Carriage of Dangerous Goods by Rail
RRN = REACH Registration Number
SGG = Segregation Group
T = Toxic
vB = Very Bioaccumulative
vM = Very Mobile
vP = Very Persistent
vPvB = Very Persistent and Very Bioaccumulative
vPvM = Very Persistent and Very Mobile

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Not classified.	

Full text of abbreviated H statements

Not applicable.

Full text of classifications [CLP/GHS]

SECTION 16: Other information

Not applicable.

Date of issue/ Date of revision : 28/03/2025

Date of previous issue : 28/11/2023

Version : 3

Notice to reader

Disclaimer: The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.